Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 2(3)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06973720Phase 2Active Not Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Role: lead

NCT06712836Phase 2Active Not Recruiting

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

Role: lead

NCT07311850Phase 3Recruiting

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Role: lead

NCT06897202Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Role: lead

NCT07022977Phase 1Active Not Recruiting

A Study of MET233 in Individuals With Obesity or Overweight

Role: lead

NCT06924320Phase 1Recruiting

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Role: lead

NCT06857617Phase 1Completed

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

Role: lead

All 7 trials loaded